How can oral paediatric formulations be improved? A challenge for the XXI century

Miguel Moreira1, Mafalda Sarraguça1

  • 1LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.

Insights

Improving pediatric oral formulations is crucial due to safety risks from off-label use. Innovative strategies like crystal engineering and 3D printing are needed to enhance drug palatability and compliance in children.

Area of Science:

  • Pharmaceutical Sciences
  • Pediatric Medicine
  • Drug Delivery Systems

Background:

  • Paediatric oral formulations require significant improvement to ensure patient safety and efficacy.
  • Lack of approved paediatric medicines leads to off-label prescribing, increasing adverse drug reaction risks.
  • Product acceptability, influenced by user and product characteristics, is vital for paediatric medication formulation.

Purpose of the Study:

  • To provide an overview of paediatric oral formulations, focusing on palatability challenges.
  • To discuss innovative approaches for improving the palatability of paediatric medicines.
  • To highlight advancements in developing specialized paediatric drug delivery systems.

Main Methods:

  • Review of current literature on paediatric oral formulation development.
  • Analysis of regulatory guidelines for paediatric medicine specialization.
  • Exploration of innovative palatability enhancement techniques.

Main Results:

  • Oral solid dosage forms are preferred over liquids for improved stability and shelf-life.
  • Palatability and size remain significant challenges for paediatric solid dosage forms.
  • Innovative methods like crystal engineering, candy-like forms, and 3D printing show promise.

Conclusions:

  • Enhancing palatability is essential for improving medication compliance in children.
  • Novel approaches are necessary to overcome existing palatability issues in paediatric formulations.
  • Crystal engineering, novel pharmaceutical forms, and 3D printing offer promising avenues for paediatric drug development.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
144
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
107
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Bioavailability Enhancement: Drug Solubility Enhancement01:16

Bioavailability Enhancement: Drug Solubility Enhancement

Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
123
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
134
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
90